Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
of possible interest.. video from Wall Street Journal on the ineffectiveness of rehab facilities that do not offer MAT...according to a Massachusetts General Hospital spokesman the effectiveness of social model inpatient rehabs that don't offer MAT, are practically nill..."relapse rate almost 100%".. "after your family may have spent ~ $60,000 on said rehab program.. we're setting up people to fail and then blame them when they don't do well"... good grief what will it take for sanity to prevail in our public policy response to this mass extinction of our citizens... one of the quotes in the addiction community that comes to mind is a quote attributed to Einstein? "insanity is doing the same thing over and over and expecting a different result".. yup.. and how many people died of overdoses in 2017?... insane
re: article.."Researchers at the South Carolina College of Pharmacy have begun the search for an orally-active KOA compound.so if they're working on oral administration".. how does that benefit TTNP.. I seem to recall that oral was a problem for K opioid .. been a while since I looked it up
Mother Jones article....the journalist chronicles his addiction & exemplifies the reason most addicts need a partial agonist instead of an antagonist like Vivitrol.. …it's not about the high .. It's about not being sick.. also interesting is this journalist's odyssey through the US & EU treatment landscape.. Granted he notes he is in the 1% who have insurance & connections to get MAT.. his goal ultimately get off all drugs.. probuphine, if approved in EU, will significantly help addicts like him taper down, even if they may require additional oral rescue meds at some point (as he did when his MD told him to take another piece of buprenorphine film)…
http://www.motherjones.com/politics/2018/01/i-was-a-successful-journalist-when-a-doctor-first-handed-me-opioids/
also of interest is the 2nd article about Braeburn's injectable vs Indivior.. I didn't know Indivior's injectable requires refrigeration while Braeburn's does not.. we will see…
"Unlike Sublocade, which requires refrigeration, CAM2038 can be stored at room temperature. The product is delivered through a technology called FluidCrystal. It is ready for use in prefilled syringes with safety devices in doses of 8 mg to 32 mg for once-weekly administration and 64 mg to 160 mg for once-monthly injections." … while the article touts the flexibility of the injectables over the 6 month implant… the reviewers do not account for the psychological limitations of recovering addicts who are tethered to weekly or monthly doctor's visits (although better than the daily methadone grind)… the real world advantage of the 6 month implant is a big deal in getting back to a normal life…IMHO
https://www.medscape.com/viewarticle/890463
interesting expose from NYT on the social model of inpatient treatment vs MAT.. I can't believe AAC only got a slap on the wrist for how they treated this patient.. treating medically vulnerable patients w/out appropriate access to physicians on site? ... driver administered sedatives w/out a prescription?.. wow.. but then again, as the article pointed out much time had elapsed since that death, so basically the legal challengers folded ... still the debate will only get sharper on appropriate evidence based treatment that avoids the minefields of patients harmed or killed by errors/omissions from the social model treatments that rely solely on "tough love"
https://www.nytimes.com/interactive/2017/12/27/business/drug-addiction-rehab.html?hp&action=click&pgtype=Homepage&clickSource=story-heading&module=photo-spot-region®ion=top-news&WT.nav=top-news
I thought everyone had disappeared from this board..nice to see you still engaged!.. even if the Feds dropped $ from helicopters.. current administration continues to believe deterrence is the best policy, they might dump more $ into law enforcement to tackle opioid addiction... lack of profit & sales from TTNP is the problem .. investors dumping end of year to offset monster profits elsewhere.. we'll see what the new year brings.. I didn't understand the CTO request .. while it might be attached to the EU deal.. they were pretty open about details & walkaway conditions from investor.. so what would TTNP want to shield from competitors that they can't share w/their investor/owners?.. in any event, TTNP is pretty oversold right now, so a trading snap back will pop it soon (unless of course there's something squirrely going on).. but in order for sustained break out.. only meaningful news from TTNP.. like a buyout, will do the trick IMHO
price is an issue & if it was < costly it would spur volume which would = + revenue.. several other disadvantages predominate right now vs injectable.. 1. injectable can be initiated immediately.. no waiting to prove stabilization for 6 months.. that is a huge hurdle.. (probuphine only appears to be approved for maintenance)..2. no REMS problems w/providers.. the shot can be administered probably by an LVN.. no need for MD/NP specially trained to perform a minor surgical procedure.. so it appears that injectables are > provider friendly than the implantable... but from a patient centered perspective, the power of the implant right out of the gate following detox is invaluable.. providing steady state for 6 months, even if MD may need to supplement occasional oral supplement & then titrate the oral down as needed... every person is different & docs need the flexibility to tailor treatment for each patient in order to assure a successful outcome... I don't understand why Braeburn has not approached the FDA to change the availability of probuphine as a fist line treatment.. why hasn't TTNP?.. they're obviously doing so in EU as their "partner" insists on that level of approval else they will walk away... why have they not re-applied in the US?... there's a new FDA perspective & no one has jumped on this at all... undoubtedly lots of stuff we don't know vs all the players.. like does Apple Tree think it can compete w/Indivior's marketing juggernaut for a me-too injectable?.. is Braeburn even a viable cash burn bottomless pit for Apple Tree going forward?
ditto!.. thanks for the link...
right on... even a little itty bitty company like Molteni is placing caveats on the viability of the TTNP lemonade stand... 1. they'll give them €2 mil but the rest has conditions.. Molteni wants full label as it "will have the right to terminate the licence agreement if the broad label is not approved by the EMA".. the additional €1mil will be sliced to 1/2 if TTNP doesn't get the EMA approval by 9-30-19 AND TTNP will have to provide Molteni w/semi finished product (implant, applicator & related technology).. back to the lemonade stand .. if successful, Molteni gets all this for less than the price of a Bay Area condo.. what a deal... only hope now is OPNT antagonist might be viable enough to get this company sold.. sheesh
we are doomed... but honestly the last administration didn't do much to react to this ballooning problem either, much less get in front of it.. still.... smoke and mirrors at this juncture is all we're getting and no one is calling them out?.. Nancy Reagan's "just say no" message to youth was understandable back in the day (it didn't work).... it's indefensible today because we know, or should know, better
Sadly we do have prisons within prisons.. in California they are called Administration Segregation Units (ASU)... if a prisoner breaks a rule they are given an RVR (rule violation) which is adjudicated by a correctional
Sergeant or Lieutenant .. if found guilty they are placed in ASU & get time added to whatever term they're serving.. as well as loss of privileges... at one time, if an inmate attempted suicide and survived, they were given an RVR and sent to ASU for wasting State time.. a lawsuit stopped that practice... today if custody staff catch a prisoner using drugs or drinking, they get an RVR and go to ASU (the prison in a prison) instead of treatment... this in the progressive state of California.. all one has to do is ask the State to provide the numbers of RVR's monthly they process for substance abuse among current inmates, to substantiate the depth of the problem and the futility of attempting to stop a behavior by punishment instead of treatment.. anybody enforcing the Mental Health and Substance Abuse Parity Act in California prisons? nope
we're gonna arrest & prosecute ... that's how were gonna lick this thing... this has been focus of administration from the start..why would anyone expect any change in priorities?.. simple fact: in our prisons, behind 12' fences topped w/barbed wire, a 6 ft space followed by another 12' ELECTRIFIED fence under the direct observation of gun toting officers... a flourishing drug trade.... we've already caught them, tried them, imprisoned them .. how does Kelly and Sessions explain they're gonna tackle that?.. just google prison drug use... the administration has no clue
limping right along.. and if that payment counts toward royalty covenant as you say.. they get another few mill at loan shark interest rates, well that allows Sunil & Co and the Board to keep drawing a paycheck, the lenders to feed off the interest rate & warrants risk free... what's left for the shareholders? not much right now.. hence the current stock price.. and again if Rubin & Sunil keep selling TTNP intellectual property here & there for pennies.. that limits their ability to sell the company.. so far, more of the same.. hence the stock price
Turks, I don't know about timeline .. Doc is probably more adept @ answering .. the only thing I would say is improbable is Braeburn being involved as they strike me as having no depth in clinical understanding of this field.. they've rolled out their products by using the OLD & INEFFECTIVE formula in their marketing .. train the docs, buy them & their staff lunch = sales w/out understanding the end users, the competitors, the regulatory environment or the legal and political field.. but then again.. TTNP picked them in the first place, so who knows
interesting they did not divulge the nature of the inquiry... if it has to do w/their lobbying the wardens & courts only to promote Vivitrol over Buprenorphine..not such a big deal in light of the fact that 2 recent research papers validated equivalency .. added to the fact that Vivitrol is not subject to diversion, they can legitimately claim superiority in a prison setting ... diversion is a very big problem in prisons loaded w/contraband .. if, on the other hand, ALKS took it up a notch & did something illegal to gain a foothold in that setting, then that's a whole other matter..
the potential for this implant is the steady state medication administration to allow the suffering addict to orient thought to getting a chance at life instead of the constant focus on where the next hit is coming from.. EVA, even dispensing the antagonist, is a god-send ... set it & forget it... the problem that I see & I think ALKS is starting to address.... is that Govt, w/the best of intentions, but failed insight, has placed such hurdles on these therapies, theoretically to prevent "abuse" .. the DEA.. the REMS..that instead of solving the problem, the regulations maintain it & perpetuate misery on those afflicted w/addiction...for example, addicts are generally required to travel to SAMHSA approved methadone clinics at 4am & line up to get their daily fix.. every day.. I know how long it takes me to get up and go to work & I have work to go to.. so how do we expect these folks to even think of looking for work when they're tied w/a ball and chain to a SAMHSA approved methadone clinic every day of their lives?.. no wonder they then go out & shoot up some Heroin (known on the street as "chipping") to dull the pain of their daily existence .. the docs that run these clinics get their daily $ aided and abetted by the govt regulations...SAMHSA & NIDA should be ashamed of themselves... MAT (ALL FDA approved MODALITIES).. should be available to every medical facility period so the doctor and the patient can decide what best fits the patient's needs for recovery.... otherwise there's no end in sight ... all that being said, TTNP management has proven their ineptitude over and over and over.. hope someone buys them out soon
very possible.. wish I was a fly on the wall at apple tree, OPNT, TTNP ALKS & INVVY.. lots of swirling scenarios & too much asymmetric information I don't have a clue about, though I'd love to speculate just for fun.. "Double, Double, Toil and Trouble" there is a witch's brew cooking in the industry.. so something's gotta give soon... I hope
X:Bot results in the Lancet... yes random selection prior to detox favored Buprenorphine .... "However, once initiated, both medications were equally safe and effective" a score for Alkermes... the key is determining where the client is in their readiness for change & prescribing accordingly.. there is no one size fits all & things can change in a heartbeat...
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2817%2932812-X/fulltext?elsca1=tlxpr
New digital pill approved by FDA.. licenced by makers of Abilify.. now that's a compliance tool I can see taking market share from injectables .. in the addiction field, psychiatric field, & beyond... thought the procedure sounded familiar so I checked my notes & sure enough Proteus (private) had presented @ Gov Christie's Panel on Addiction.. I thought they were a little far afield at the time w/their digital pills.. I was wrong & am dully humbled
http://www.foxnews.com/health/2017/11/14/fda-approves-digital-pill-that-tracks-when-patients-take-it.html
1. Braeburn injectable not a done deal.. while FDA's Gotlieb has complained ~delay in approval due to statistical focus of the FDA.. didn't hear him gloss over safety & efficacy.. some on that panel for the injectable had valid concerns...
2. I thought it was telling that Braeburn CEO only mentioned the injectable @ the addiction meeting.... no mention of probuphine... I don't know anything about Mike or the current constraints Apple has placed on him but his presentation at the meeting was underwhelming.. if I had control of probuphine I would have approached FDA about revising REMS in light of the opiate epidemic AND would have asked the Addiction Panel's help in expediting.. what a megaphone opportunity squandered
wee bit credibility problem from Zacks as they keep ratcheting down thier estimates...anybody recall their former predictions?... didn't see any mention of TTNP sale in the report, which if they don't move on quickly will severely limit their maneuverability... interesting disclosure fine print @ end of report
" The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request."
I particularly chuckled at the report's praise for Braeburn's new CEO.. Mike will fix everything
as far as the touted cash on hand, a big hunk of the $ is the loan they got at payday rates .. the monthly interest payment is heavy & secured by all their assets, except intellectual property.. for now
all is not assured for the injectables ..not for Braeburn or INVVY... at some point Apple Tree may pull the plug on Braeburn rather than pour another nickel into mounting losses (could be happening right now) .. remember from S1, that was one of the concerns of auditors?... no one's buying Braeburn's song.. so someone may step up & swoop the whole caboodle at a discount .. TTNP & probuphine from Apple Tree..we'll see
https://www.medpagetoday.com/psychiatry/opioids/68965
yup.. retailing 101.. as I said before $ pays the bills not gross margin %.. elementary math..I was shopping at a farmer's market yesterday.. magic marker on cardboard sign for shelled walnuts $4.99.. by the time I walked back past the stand, the .99 had been crossed off & buyers were clustering :).. ..again to reiterate (broken record, I know) .. probuphine needed to to be comparable to sublingual w/a slight boost for long term steady state until adoption & demand was assured... would have prevented pre-approval barriers IMHO..... dumb management, dumb Board, dumb me for maintaining even a negligible position.. still I have learned a lot that I'm applying to other investments, so not a total loss..
agree Braeburn still has no clue if they think they can make $ w/injectable they licenced against INVVY injectable.. but it's not all on them.. TTNP gave them the ball and walked away hoping for the best.. then they did exactly what all this time? I'd like to see the daily schedule of each TTNP employee..& the 2 sentence goals the Board has set for continued remuneration of the same inept management.. oh right Board just rubber stamps.. a larger company has the resources to move the pre-clinical trials, the manufacturing, the marketing, etc, right quick so there is some value there in the implant technology but not if it is not sold soon as competitors abound and patents expire quickly
EU application submitted Nov 6.. what took so long? oh I know had to do something before the 9th else the earnings press release would have been a blank page... "discussions w/potential commercial partners.. ongoing".. they've been ongoing for years... right, we had to fill space in the press release... "we are in discussions w/Braeburn senior management to fully understand all of these issues".. Braeburn doesn't understand.. good grief... save the ink (digital or otherwise) and issue simple statement "we're not making any money .. never have.. probably never will unless someone lights a fire under us to sell the company NOW
I agree it's up to the doc and the patient.. clearly bribing folks is illegal..not sure anyone has accused ALKS of doing anything close to that .. and to be fair, I was in the addiction field back in the day when those who wanted to use Vivitrol to help keep them sober couldn't access the drug unless they had the bucks to pay out of pocket, as most insurance did not cover it.. Medical certainly did not..things have changed... as far as TTNP is concerned.. seems as though the stock price is reflecting poor sales of probuphine .. volume pressure continues on the downside... we will know on Thurs.. hope they can pull a rabbit out of the hat
caveat emptor.. as long as they did not misrepresent the risks of their product.. well then it's on the purchasers (wardens, judges, etc) to research other treatment modalities.. ALKS is responsible for pitching their product.. just like any other retailer.. I doubt if Braeburn's sales reps or Indivior's are educating the doctors they meet on the virtues of Vivitrol
Sharp punch back from ALKS & hews to the line CEO outlined at the Govt meeting on addiction.... one size doesn’t fit all… EVERY treatment modality must be available to clinician & patient for customization which will statistically increase the likelihood of a successful outcome… Harris is digging into historical claims ALKS sales reps made to wardens in jails & local politicians that likely marketed the efficacy of Vivitrol at the expense of the other modalities despite ALKS CEO's recent eloquent statements.... still, if ALKS continues to emphasize its current mantra, Harris will have an uphill road to take any scalps right now… interesting the note that “the blockade produced by Vivitrol is surmountable”.. anyone who has worked w/the addicted can attest that they are generally as adept as chemists, or think they are, in their ability to fool standard urinalysis tests & get high despite the use of mandated antagonists (like when a patient is coerced to take the shot and not yet committed to sobriety) … “the plasma concentration of exogenous opioids attained immediately following their acute administration may be sufficient to overcome the competitive receptor blockade” … and by the same token, the addicts who think they can outwit the chemical constraints of Vivitrol by using Heroin say, on the 25th day following injection, as the blockade of the antagonist ?, the response from ALKS goes on to state.. “use of previously tolerated doses of opioids could result in potentially life-threatening opioid intoxication…cases of opioid overdose with fatal outcomes have been reported in patients who used opioids at the end of a dosing interval, after missing a schedule dose, or after discontinuing treatment”… oh and in an emergency when they need narcotics to deal w/pain?… not an option unless patients are “closely monitored by trained personnel in a setting staffed and equipped for CPR (sounds like an ICU)”… well an implant can just be removed in those circumstances… advantage proneura!
thanks
ALKS .. more
Kamala may not have the clout just yet to compel info from ALKS in the Senate.. but she has the pull to get the AG in California to compel answers from ALKS on the state level... stay tuned.. whatever happened to the Indivior lawsuit on suboxone? anyone?.. I've lost track
http://www.sacbee.com/latest-news/article182992931.html
ouch ALKS.. Sen Kamala Harris out looking for scalps.. may explain why ALKS CEO during opiate panel took pains to state that antagonists not the only treatment modality that is valid...he knew this was coming no doubt
https://www.harris.senate.gov/content/senator-harris-launches-investigation-pharmaceutical-manufacturer-alkermes-regarding-opioid
ALKS has the cash to buy TTNP & possibly US licence from Braeburn (if sales are bad this quarter) & promote both antagonist and agonist therapy as well as to broaden the scope of proneura delivery system for other indications.. in any case ALKS has the manufacturing capacity in Ireland to competitively roll out this technology.. for sure in EU & elsewhere
things change.. FDA chief Gottlieb, TODAY has committed to > aggressive approval of interventions for opioid addiction... I don't foresee Braeburn going to bat to revisit the stabilization issue for Probuphine.. not while they have injectable approved... the upshot is how much sales penetration they will have vs Indivior .. to me it appears > efficacious to opt for the steady stream of medication offered by the 6 month implant vs the monthly injectables.. but we'll see what the adoption rate will be among patients & their doctors.. not to mention the insurance profiteers...who knows, maybe Braeburn may go back to FDA on Probuphine... in the meantime, I'll take the risk of being labeled a broken record... "Sell the Company Now"
understand your frustration..timing is everything.. the opioid crisis was not as front & center when FDA was evaluating Probuphine.. virtually anyone today gets an easy pass, given the climate of urgency surrounding opiate addiction.. the problem is TTNP has no time and virtually no cash.. and the price continues to reflect this until something material changes.. November.. we will know soon if they met royalty benchmarks to meet one of their loan covenants.. right now they still are behind in meeting the 2nd benchmark on market capitalization (valued < than 50 mil)... still no news on EU approval, the 3rd loan covenant.. until something changes, all the rest is amusement and amazement.. best outcome right now is to sell the company
Vivitrol..ALKS conference call ...I detected mgmt was wee bit concerned ~ study completed (head to head vivitrol vs buprenorphine for OUD, (X:BOT) that has yet to be published .. study conducted by NIDA & NYU school of medicine .. possibly a tad more rigorous than the Norway study which had some limitations... "Limitations of the study, as noted by the study investigators, include lack of blinding between treatment arms, and the possibility that the patient population in the study may have been motivated to receive the novel antagonist treatment of extended-release naltrexone, which is unavailable in Norway".. mgmt said the X:BOT study randomized the population BEFORE the detoxification process, over ALKS objections... so not all smooth sailing for the antagonists.. mgmt continues to argue, and rightly so, that ALL FDA approved MAT should be available to every patient.. treatment to be decided by doctor and patient.. period... the Trump national emergency declaration was expected to be meaningless.. FDA Gottlieb's point of view will hopefully have > impact.. AND the individual politicians at the state level will face challenges in attack ads if they don't mount a robust response to this crisis...
https://www.drugabuse.gov/about-nida/organization/cctn/ctn/research-studies/extended-release-naltrexone-vs-buprenorphine-opioid-treatment-xbot
JAMA study Vivitrol vs oral Buprenorphine.. headline notes non-inferiority of Vivitrol .. but "More patients reported adverse events in the extended-release naltrexone group versus those in the buprenorphine-naloxone group (69.0% vs. 34.7%). A number of events in the extended-release naltrexone group, and to a lesser degree in the buprenorphine-naloxone group, were related to induced or experienced withdrawal symptoms, which the study investigators attribute largely to insufficient opioid detoxification. A change to the detoxification strategy was made during the first year of the study, which reduced the number of new adverse events related to induction of treatment"… so the study was changed to redefine detoxed folks as those who don't have cravings?.. don't know... haven't seen study methodology.. anyone out there combed through the details?
From <http://www.businesswire.com/news/home/20171018006067/en/New-Study-Comparing-Effectiveness-Extended-Release-Naltrexone-Buprenorphine-Naloxone>
I did listen to the broadcast..way too long > 3 hours.. grandstanding standard pap.. participants seemed uninterested, Pam Bondi on her smart phone..didn't she get she was being filmed?.. couldn't she turn on her mike when she offered whatever remarks she did?.. I zipped through the insurance presentations but did listen to Kaiser BC they have an all encompassing model of care delivery they tightly control: outpatient, inpatient, pharmacy; doctors are salaried.. their model circumvents the doc on the street & would be ideal distribution channel for probuphine because they are HUGE w/millions of members.. I did listen to the Government representatives incl the dep attorney general... don't have time or space to comment on inconsistencies, stupidities, & continued fumbling of care... yes, as the article points out, Kennedy's remarks were spot on and so were Governor Baker's who cut to the chase.. to paraphrase, he said...what are you all measuring regarding the effectiveness of treatment you pay for.. this is a revolving door of relapse and no one is being held accountable... Gov Baker & Kennedy should take their show to Congress for action!.. oh and Alex Acosta on enforcing the parity law? not.. he seemed proud of the fact that his dept in June experimented w/people's lives who are on workers comp by requiring "prior authorization and a letter of medical necessity for opioids" .. so that caused an immediate spike in scripts before the policy took effect "and then we had a drastic drop, almost none".. doh! you think some went out to the corner street for heroin?.. give me strength
will have to wait & see how the administration will define the level of intervention it deems appropriate to stem the deaths ...how much $ they will allocate toward interdiction vs treatment... my hope is that they immediately enforce the MH&SA Parity act of 2010,7 years later...(like where was the last administration on enforcing this law?) ...AND they declare that insurance companies MAY NOT ask for pre-approval for any FDA approved drugs ordered by a physician AND insurance will pay for inpatient without question if an MD orders it... period... Braeburn will benefit and so will TTNP... remember though that the Probuphine implant is restricted to a STABLE patient, thus it will generally not be the first remedy that's offered... still the administration has extensive powers it can apply... but I'll wait until I see it in print... one thing is certain, this is a political hot potato right now and there will be no place to hide for any politician who does not fully support whatever it takes to stop this scourge
agree.. but any price, royalty or buy out, will be discounted based on time to the patent expiration... so it makes sense to sell the company quickly instead of burning time on trials etc that even if successful may render the exclusivity a moot point as any pharma can simply wait and manufacture a generic... similar scenario that Braeburn may be facing w/probuphine.. (spent their $ to train MD.. .. then OPNT, ALKS, TTNP comes waltzing in to the trained MD's office w/out spending a penny:).. trials take time & a large pharma has resources to truncate the time ... TTNP does not
while not a conflict, there are downsides to "partnering or licensing" to segments of the industry... a piece there & a piece here and pretty soon no one is interested in buying the platform as there are too many pieces to retrieve to give anyone control & the patent limps toward expiration not to mention a competitive assault that could wipe out any advantage in the drug delivery system .. TTNP management is long in the tooth w/out deep pockets to quickly bring anything to market ... they need to sell the company period in order to maximize shareholder value... yes Braeburn should be very upset @ collaboration w/OPNT on using the EVA for antagonist to opiate addiction... Braeburn has spent a fair amount of coin training the MD's who now may have the option to implant either an antagonist or an agonist.. Akin to TTNP & OPNT getting a free ride from Braeburn... ALKS also stands to lose market share if the antagonist is successful... I can see Apple Tree possibly buying TTNP if they continue to support Braeburn, otherwise everyone will limp along if TTNP does not find a buyer.. 3 key things to keep in mind relative to the loan agreement they signed coming up in the short term... by year end they have to meet the following in order to get another 3 mil in 2018: 1. market cap of 50 m (they're close, price >2.5 would do it); 2. royalty income of not < than $750,000 (who knows); 3.Execution of a partnership or similar agreement for the marketing and sale of Probuphine in Europe (if they get EU approval that should suffice)... the short interest decline is a good sign.. many covered, but TTNP needs to FU by aggressively marketing the company for a buyout .. all the rest is noise
I worked @ a 6 month residential substance abuse facility paid for by CPS for women who had delivered drug addicted babies...licenced day care providers tended to the infants while the mothers worked on their recovery.. the caretakers did their best to soothe the hyper sensitive infants who would screech at the slightest noise.. a caretaker explained that even the intrusiveness of bright fluorescent lights would irritate the nervous system of these hypersensitive newborns... I've never forgotten.. there is not an easy fix for addiction recovery... the Alkermes CEO made that pointy to Gov Christie's panel.. no one size fits all that will effectively address this national epidemic... the depth of this scourge has savaged many lives @ every level of the social strata & politicians who fail to address it, will do so at their peril
EU may be 1/10 the market for opiate addiction.. still a greater part of the pie to TTNP if they negotiate a sharper deal w/partner... but > importantly it validates their drug deliver system... bottom line that's what TTNP is selling... the delivery system... not a specific drug